{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-312390","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2026-07-22T20:05:15+00:00","discovered_at":"2026-07-22T20:06:01.283937+00:00","generated_at":"2026-07-22T20:06:17.867725+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"NewAmsterdam COO Douglas Kling resigns to become CEO of another biotech; transition expected","bullets":["Douglas Kling notified resignation as COO effective August 14, 2026.","Kling will become CEO of another clinical-stage biotech company.","Company expects separation agreement and advisor agreement for transition services.","Advisor role will focus on PREVAIL clinical trial of obicetrapib and other programs.","No replacement for COO announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-312390","json":"https://secwatch.observer/filing/0001193125-26-312390.json","markdown":"https://secwatch.observer/filing/0001193125-26-312390.md","text":"https://secwatch.observer/filing/0001193125-26-312390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526312390/0001193125-26-312390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526312390/nams-20260716.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-22T20:06:17.867725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}